MedPath

evaluation of atherosclerotic vascular lesions and terminal diseases as well as cardiovascular risk factors and experimental biomarkers in patients with primary sjögren-syndrome

Conditions
M35.0
I70.9
Sicca syndrome [Sjögren]
Generalized and unspecified atherosclerosis
Registration Number
DRKS00026261
Lead Sponsor
Medizinische Hochschule Hannover in Kooperation mit der Else-Kröner-Fresenius-Stiftung
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
317
Inclusion Criteria

Inclusion criteria for patient population:
- Age of majority (>18)
- ability to give informed consent is given
- confirmed diagnosis of primary Sjögren's syndrome (at least 2/3 criteria from the classification criteria for pSS of the American College of Rheumatology/European League Against Rheumatism 2016)
- At least 5 years cancer free survival

Inclusion criteria for control subjects:
- Age of majority (>18)
- Ability to give informed consent is given

(matched recruitment by age and sex to patient population).

Exclusion Criteria

Exclusion criteria for pSS patients
- Active cancer or cancer that occurred less than five years ago.
- Incapable of giving informed consent
- not at the age of majority (>18 yrs.)
- Pregnancy
- Not fulfilling at least 2/3 classification criteria as defined by the American College of Rheumatology/European League Against Rheumatism of 2016.
- known arterial occlusive diseases (peripheral arterial occlusive disease, coronary heart disease, stroke, myocardial infarction)
Exclusion criteria for control subjects
- not at the age of majority (>18 yrs.)
- Incapable of giving informed consent
- Active cancer or cancer that occurred less than five years ago
- Pregnancy
- known arterial occlusive diseases (peripheral arterial occlusive disease, coronary heart disease)
- known underlying rheumatic/inflammatory diseases, especially vasculitides, rheumatoid arthritis or systemic lupus erythematosus

Study & Design

Study Type
observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath